ClinicalTrials.gg
Active, not recruitingNCT02717611Updated Mar 25, 2026Results posted

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

A Phase 2 interventional study of ACP-196 (acalabrutinib) in Chronic Lymphocytic Leukemia, sponsored by Acerta Pharma BV. Active, not recruiting at 23 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 11 open to participants now, 28 under way, 6 of them phase 3. acalabrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
21st of 39
60 · median 61
Started
2016
with 1 other
Phase 2
22 of 39
8 open now
Primary completion
2020-10
later than 2 of 27 live
Registered
7th of 39
by date
Lead sponsor
9 of 39
Acerta Pharma BV

Among the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 21st largest by enrollment, is one of 2 that started in 2016, is one of 22 in phase 2, reaches primary completion later than 2 of the 27 other live ones, and was the 7th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

11 of the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About acalabrutinib

acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

A Phase 2 Study to evaluate the Efficacy and Safety of ACP-196 (acalabrutinib) in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Read the detailed description

A Multicenter, Open-Label, Phase 2 study evaluating the efficacy and safety of Acalabrutinib in subjects with relapsed/refractory CLL (N=60) who are intolerant of ibrutinib therapy.

03

Conditions studied

  • Chronic Lymphocytic Leukemia

Keywords

  • Chronic Lymphocytic Leukemia
  • Ibrutinib Intolerant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women ≥ 18 years of age.
  2. Prior diagnosis of CLL
  3. Must have received ≥ 1 prior therapy for CLL
  4. Intolerant of ibrutinib
  5. Documented disease progression after stopping ibrutinib therapy as defined by the IWCLL 2008 criteria
  6. Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty.
  7. performance status of ≤ 2.

Exclusion criteria

Exclusion Criteria:

  1. Ongoing AE attributed to ibrutinib therapy
  2. Treatment with systemic anticancer therapy for CLL is prohibited between discontinuation of ibrutinib and enrollment on this trial.
  3. Prior exposure to a BCL-2 inhibitor (eg, venetoclax/ABT- 199)
  4. Prior (other than CLL), except for adequately treated basal cell or squamous cell skin cancer, in situ cancer, or other cancer from which the subject has been disease free for ≥ 2 years.
  5. Significant cardiovascular disease such as uncontrolled or symptomatic untreated arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the Functional Classification, or > 480 msec at screening. Exception: Subjects with controlled, asymptomatic atrial fibrillation during screening are allowed to enroll on study.
  6. Malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of the stomach, extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
  7. Evidence of active Richter's transformation or any evidence of disease progression on ibrutinib therapy or any BTK inhibitor.
  8. CNS involvement by CLL or related Richter's transformation.
  9. Known history of (HIV), serologic status reflecting active or C infection, or any uncontrolled active systemic infection.
  10. Uncontrolled hemolytic anemia (AIHA) or idiopathic thrombocytopenic purpura (ITP)
  11. History of stroke or intracranial hemorrhage within 2 months before the first dose of study drug.
  12. History of bleeding diathesis.
  13. Presence of a gastrointestinal ulcer diagnosed by endoscopy within 3 months before screening.
  14. Major surgical procedure within 28 days of first dose of study drug.
  15. Requires treatment with a strong inhibitor
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    ACP-196 (acalabrutinib)

    ACP-196 (acalabrutinib) 100 mg to be administered orally (PO) twice a day BID

    Drug: ACP-196 (acalabrutinib)

Interventions

  • ACP-196 100 mg to be administered orally (PO) twice a day BID.

    Also known as: Acalabrutinib

06

What researchers measure

Primary outcomes

  1. The Overall Response Rate (ORR) of ACP-196 (Acalabrutinib)

    The overall response rate (ORR) of ACP-196 (acalabrutinib) in subjects with relapsed / refractory CLL who are intolerant of ibrutinib therapy. ORR is defined as the proportion of subjects achieving a best overall response (BOR) of either complete remission (CR), complete remission with incomplete bone marrow recovery (CRi), nodular partial remission (nPR), or partial remission (PR) at or before initiation of subsequent anticancer therapy. ORR will be analyzed per investigator's assessment.

    Time frame: From date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 4 years and 7 months). 1 cycle = 28 days

Secondary outcomes

  1. Progression-Free Survival

    The progression-free survival of ACP-196 (acalabrutinib) in subjects with relapsed / refractory CLL who are intolerant of ibrutinib therapy. PFS is calculated as date of disease progression or death (censoring date for censored subjects) - first dose date + 1.

    Time frame: From the date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years).

  2. Duration of Response

    The duration of response of ACP-196 (acalabrutinib) in subjects with relapsed / refractory CLL who are intolerant of ibrutinib therapy. DOR is calculated as date of disease progression or death (censoring date for censored subjects) - date of achieving the first CR, CRi, nPR, or PR + 1.

    Time frame: From the date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years)

  3. Time-to-Next Treatment

    The time to next treatment of ACP-196 (acalabrutinib) in subjects with relapsed / refractory CLL who are intolerant of ibrutinib therapy. TTNT is defined as the time from date of first acalabrutinib treatment to date of institution of subsequent anticancer therapy for CLL or death due to any cause, whichever comes first. Subjects who do not have the above specified events prior to the data cutoff date will be censored at the date of last visit. TTNT will be calculated as follows: (Earlier date of institution of subsequent anticancer therapy for CLL or date of death due to any cause) - date of first dose + 1. For censored subjects, date of last visit will replace earlier date of use of subsequent anticancer therapy for CLL or date of death due to any cause in the calculation.

    Time frame: From date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years)

  4. Overall Survival

    The overall survival of ACP-319 (acalabrutinib) in subjects with relapsed/refractory CLL who are intolerant of ibrutinib therapy

    Time frame: From date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years).

07

Results

Posted Feb 9, 2022

Participant flow

Participant flow — Overall Study
MilestoneAcalabrutinib
Started60
Completed0
Not completed60
Withdrew: Death13
Withdrew: Withdrawal by subject6
Withdrew: Active, not recruiting40
Withdrew: Complicating disease1

Outcome measures

PrimaryThe Overall Response Rate (ORR) of ACP-196 (Acalabrutinib)

The overall response rate (ORR) of ACP-196 (acalabrutinib) in subjects with relapsed / refractory CLL who are intolerant of ibrutinib therapy. ORR is defined as the proportion of subjects achieving a best overall response (BOR) of either complete remission (CR), complete remission with incomplete bone marrow recovery (CRi), nodular partial remission (nPR), or partial remission (PR) at or before initiation of subsequent anticancer therapy. ORR will be analyzed per investigator's assessment.

Time frame:
From date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 4 years and 7 months). 1 cycle = 28 days
Reported as:
Number · Percentage of participants
The Overall Response Rate (ORR) of ACP-196 (Acalabrutinib)
Percentage of participantsAcalabrutinib
The Overall Response Rate (ORR) of ACP-196 (Acalabrutinib)70.0 (56.8 to 81.2)
SecondaryProgression-Free Survival

The progression-free survival of ACP-196 (acalabrutinib) in subjects with relapsed / refractory CLL who are intolerant of ibrutinib therapy. PFS is calculated as date of disease progression or death (censoring date for censored subjects) - first dose date + 1.

Time frame:
From the date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years).
Reported as:
Median · Months
Progression-Free Survival
MonthsAcalabrutinib
Progression-Free SurvivalNA (33.7 to NA)
SecondaryDuration of Response

The duration of response of ACP-196 (acalabrutinib) in subjects with relapsed / refractory CLL who are intolerant of ibrutinib therapy. DOR is calculated as date of disease progression or death (censoring date for censored subjects) - date of achieving the first CR, CRi, nPR, or PR + 1.

Time frame:
From the date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years)
Reported as:
Median · Months
Duration of Response
MonthsAcalabrutinib
Duration of ResponseNA (29.9 to NA)
SecondaryTime-to-Next Treatment

The time to next treatment of ACP-196 (acalabrutinib) in subjects with relapsed / refractory CLL who are intolerant of ibrutinib therapy. TTNT is defined as the time from date of first acalabrutinib treatment to date of institution of subsequent anticancer therapy for CLL or death due to any cause, whichever comes first. Subjects who do not have the above specified events prior to the data cutoff date will be censored at the date of last visit. TTNT will be calculated as follows: (Earlier date of institution of subsequent anticancer therapy for CLL or date of death due to any cause) - date of first dose + 1. For censored subjects, date of last visit will replace earlier date of use of subsequent anticancer therapy for CLL or date of death due to any cause in the calculation.

Time frame:
From date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years)
Reported as:
Median · Months
Time-to-Next Treatment
MonthsAcalabrutinib
Time-to-Next Treatment44.0 (27.4 to NA)
SecondaryOverall Survival

The overall survival of ACP-319 (acalabrutinib) in subjects with relapsed/refractory CLL who are intolerant of ibrutinib therapy

Time frame:
From date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years).
Reported as:
Median · Months
Overall Survival
MonthsAcalabrutinib
Overall SurvivalNA (NA to NA)

Adverse events

Collected over From first dose of study drug until 30 days post last dose through study completion. An average of 5 years.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Acalabrutinib13/60 (21.7%)32/60 (53.3%)60/60 (100%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventAcalabrutinib
PneumoniaInfections and infestations7/60
SepsisInfections and infestations3/60
SyncopeNervous system disorders3/60
Cardiac failure congestiveCardiac disorders2/60
Non-cardiac chest painGeneral disorders2/60
Bronchopulmonary aspergillosisInfections and infestations2/60
DyspnoeaRespiratory, thoracic and mediastinal disorders2/60
AnaemiaBlood and lymphatic system disorders1/60
Atrial fibrillationCardiac disorders1/60
Ventricular fibrillationCardiac disorders1/60
Most frequent other events
Showing 10 of 352
Most frequent other events
EventAcalabrutinib
DiarrhoeaGastrointestinal disorders32/60
ContusionInjury, poisoning and procedural complications26/60
HeadacheNervous system disorders26/60
Upper respiratory tract infectionInfections and infestations20/60
DizzinessNervous system disorders19/60
CoughRespiratory, thoracic and mediastinal disorders19/60
NauseaGastrointestinal disorders15/60
FatigueGeneral disorders15/60
ArthralgiaMusculoskeletal and connective tissue disorders14/60
PyrexiaGeneral disorders12/60

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Acalabrutinib
Mean69.2 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)Acalabrutinib
Female22
Male38
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Acalabrutinib
Hispanic or Latino2
Not Hispanic or Latino54
Not Reported4
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Acalabrutinib
American Indian or Alaska Native0
Asian0
Black or African American1
Native Hawaiian or Other Pacific Islander0
White56
Other1
Not Reported2
Region of Enrollment
Region of Enrollment(Participants)Acalabrutinib
United States49
Europe11
08

Study locations

23 sites
  • Research Site
    Tucson, Arizona 85704, United States
  • Research Site
    Concord, California 94520, United States
  • Research Site
    La Jolla, California 92093, United States
  • Research Site
    Palo Alto, California 94304, United States
  • Research Site
    Washington D.C., District of Columbia 20007, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Lake Success, New York 11042, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Sherman, Texas USA, United States
  • Research Site
    Seattle, Washington 98108, United States
  • Research Site
    Seattle, Washington 98122, United States
  • Research Site
    Spokane, Washington 99208, United States
  • Research Site
    Milwaukee, Wisconsin 53226, United States
  • Research Site
    Bruges, 8000, Belgium
  • Research Site
    Bordeaux, 33076, FR, France
  • Research Site
    Haifa, 31000, Israel
  • Research Site
    Madrid, 28006, Spain
  • Research Site
    Bournemouth, BH7 7DW, United Kingdom
  • Research Site
    Leeds, LS9 7TF, United Kingdom
  • Research Site
    Manchester, M20 4BX, United Kingdom
09

References and documents

Publications

  • Rogers KA, Thompson PA, Allan JN, Coleman M, Sharman JP, Cheson BD, Jones D, Izumi R, Frigault MM, Quah C, Raman RK, Patel P, Wang MH, Kipps TJ. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica. 2021 Sep 1;106(9):2364-2373. doi: 10.3324/haematol.2020.272500. PubMed 33730844 ↗
  • Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, Strelec LE, Vandegrift A, Fitzpatrick DM, Zent CS, Feldman T, Goy A, Claxton DF, Bachow SH, Kaur G, Svoboda J, Nasta SD, Porter D, Landsburg DJ, Schuster SJ, Cheson BD, Kiselev P, Evens AM. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood. 2016 Nov 3;128(18):2199-2205. doi: 10.1182/blood-2016-05-716977. Epub 2016 Sep 6. PubMed 27601462 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Oct 2020, 55 months.

Results were first posted in Feb 2022, 1 year 3 months after primary completion.

Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's 55 months is close to that.

Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2016
First posted
Mar 24, 2016
StartActual
Mar 8, 2016
Primary completionActual
Oct 16, 2020
CompletionEst.
Jun 6, 2026
Results first posted
Feb 9, 2022
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02717611
Lead sponsor
Acerta Pharma BV
Responsible party
Sponsor
First posted
Mar 24, 2016
Start date
Mar 8, 2016
Primary completion
Oct 16, 2020
Completion
Jun 6, 2026 (estimated)
Results posted
Feb 9, 2022
Last update
Mar 25, 2026

Study contacts

Acerta Clinical Trials
study director · 1-888-292-9613; acertamc@dlss.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acalabrutinib

Start the discussion